Investor Relations

Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases


Jan 10, 2022 at 11:30 AM EST
Nov 30, 2021 at 3:30 PM EST

Corporate Presentation

Print Page
Email Alerts
RSS Feeds
Investor Contacts